Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APTO Aptose Biosciences		$4.41	$1.35 ▼ $50.10	$3.66M	1.04	227,964 shs	650,294 shs
ATRA Atara Biotherapeutics	$9.23 -2.6%	$7.94	$5.01 ▼ $18.71	$55.02M	0.18	117,330 shs	23,402 shs
GNFT GENFIT	$3.65 -2.7%	$4.10	$2.55 ▼ $6.42	$182.51M	1.08	10,406 shs	5,487 shs
MGTX MeiraGTx	$8.47 -1.7%	$6.16	$3.85 ▼ $8.75	$680.69M	1.24	405,701 shs	519,251 shs
REPL Replimune Group	$10.97 +1.9%	$9.11	$6.44 ▼ $17.00	$845.64M	0.61	895,153 shs	2.30 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APTO Aptose Biosciences	0.00%	0.00%	0.00%	0.00%	-92.21%
ATRA Atara Biotherapeutics	0.00%	+15.23%	+5.97%	+66.91%	+2.33%
GNFT GENFIT	0.00%	-4.45%	-9.43%	+7.67%	-16.34%
MGTX MeiraGTx	0.00%	+12.86%	+28.53%	+62.88%	+104.59%
REPL Replimune Group	0.00%	+16.08%	+10.92%	+49.25%	+26.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APTO Aptose Biosciences	1.1588 of 5 stars	3.8	0.0	0.0	0.6	0.0	0.0
ATRA Atara Biotherapeutics	4.5544 of 5 stars	3.3	3.0	4.7	3.8	2.5	0.6
GNFT GENFIT	2.3218 of 5 stars	3.5	5.0	0.0	2.1	0.0	0.0
MGTX MeiraGTx	4.2702 of 5 stars	3.5	1.0	4.8	3.2	2.5	0.6
REPL Replimune Group	4.0717 of 5 stars	3.6	1.0	4.5	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APTO Aptose Biosciences	3.50	Strong Buy	$6.00	∞ Upside
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	92.31% Upside
GNFT GENFIT	3.00	Buy	$13.00	256.16% Upside
MGTX MeiraGTx	3.00	Buy	$24.00	183.35% Upside
REPL Replimune Group	3.13	Buy	$20.83	89.91% Upside

Current Analyst Ratings Breakdown

Latest ATRA, REPL, APTO, GNFT, and MGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/20/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
6/2/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$14.00 ➝ $22.00
5/14/2025	MGTX MeiraGTx	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $35.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
ATRA Atara Biotherapeutics	$128.94M	0.43	N/A	N/A	($16.89) per share	-0.55
GNFT GENFIT	$67.00M	2.72	$0.07 per share	52.18	$1.50 per share	2.43
MGTX MeiraGTx	$34.51M	19.73	N/A	N/A	$0.87 per share	9.74
REPL Replimune Group	N/A	N/A	N/A	N/A	$5.40 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APTO Aptose Biosciences	-$51.21M	-$89.19	N/A	N/A	N/A	N/A	-5,683.22%	-300.44%	N/A
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	-7.83%	N/A	-14.51%	8/11/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
MGTX MeiraGTx	-$147.79M	-$2.32	N/A	22.29	N/A	-484.90%	-241.05%	-62.93%	8/11/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.07	N/A	N/A	N/A	N/A	-57.98%	-45.21%	8/14/2025 (Estimated)

Latest ATRA, REPL, APTO, GNFT, and MGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/13/2025	Q1 2025	MGTX MeiraGTx	-$0.38	-$0.51	-$0.13	-$0.51	$4.44 million	$1.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
MGTX MeiraGTx	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APTO Aptose Biosciences	N/A	1.05	1.05
ATRA Atara Biotherapeutics	N/A	0.57	0.57
GNFT GENFIT	0.08	1.23	1.23
MGTX MeiraGTx	2.34	1.53	1.51
REPL Replimune Group	0.17	7.95	7.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APTO Aptose Biosciences	26.62%
ATRA Atara Biotherapeutics	70.90%
GNFT GENFIT	2.24%
MGTX MeiraGTx	67.48%
REPL Replimune Group	92.53%

Insider Ownership

Company	Insider Ownership
APTO Aptose Biosciences	1.33%
ATRA Atara Biotherapeutics	4.00%
GNFT GENFIT	4.20%
MGTX MeiraGTx	7.50%
REPL Replimune Group	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APTO Aptose Biosciences	31	2.14 million	63.45 million	No Data
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
MGTX MeiraGTx	300	80.37 million	74.34 million	Optionable
REPL Replimune Group	210	77.09 million	70.30 million	Optionable

ATRA, REPL, APTO, GNFT, and MGTX Headlines

Recent News About These Companies

Replimune Group, Inc. (REPL) Stock Competitors & Similar Stocks ...

July 12 at 2:00 AM | seekingalpha.com

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 11 at 4:01 PM | globenewswire.com

Replimune Group (NASDAQ:REPL) Shares Up 4.4% - Should You Buy?

July 7, 2025 | marketbeat.com

Moody Aldrich Partners LLC Makes New $1.93 Million Investment in Replimune Group, Inc. (NASDAQ:REPL)

July 4, 2025 | marketbeat.com

HC Wainwright Reaffirms Buy Rating for Replimune Group (NASDAQ:REPL)

July 4, 2025 | americanbankingnews.com

Replimune Group (NASDAQ:REPL) Earns "Buy" Rating from HC Wainwright

July 3, 2025 | marketbeat.com

Replimune Group, Inc. (REPL) - Yahoo Finance

July 1, 2025 | finance.yahoo.com

Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of "Buy" by Analysts

June 25, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Replimune Group (REPL) with Overweight Recommendation

June 20, 2025 | msn.com

Replimune Group (NASDAQ:REPL) Coverage Initiated at Cantor Fitzgerald

June 20, 2025 | marketbeat.com

Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE

June 14, 2025 | marketbeat.com

Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan

June 6, 2025 | quiverquant.comQ

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 6, 2025 | globenewswire.com

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

June 1, 2025 | globenewswire.com

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review

May 26, 2025 | investing.com

Earnings call transcript: Replimune Q1 2025 sees stock drop post-earnings

May 24, 2025 | uk.investing.com

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings

May 24, 2025 | nasdaq.com

Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript

May 23, 2025 | insidermonkey.com

Emily Luisa Hill Sells 2,535 Shares of Replimune Group, Inc. (NASDAQ:REPL) Stock

May 23, 2025 | insidertrades.com

Q4 2025 Replimune Group Inc Earnings Call

May 22, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?
By Gabriel Osorio-Mazilli | June 23, 2025
View Payment Giants Slide on Stablecoin Buzz—Is Now the Time to Buy?

ATRA, REPL, APTO, GNFT, and MGTX Company Descriptions

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Atara Biotherapeutics NASDAQ:ATRA

$9.23 -0.25 (-2.64%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.32 +0.09 (+1.02%)

As of 07/11/2025 07:56 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

GENFIT NASDAQ:GNFT

$3.65 -0.10 (-2.67%)

As of 07/11/2025 03:59 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MeiraGTx NASDAQ:MGTX

$8.47 -0.15 (-1.74%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$8.52 +0.04 (+0.53%)

As of 07/11/2025 05:25 PM Eastern

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Replimune Group NASDAQ:REPL

$10.97 +0.20 (+1.86%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$11.12 +0.15 (+1.32%)

As of 07/11/2025 07:55 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time